Shunji Takahashi Selected Research

Induction Chemotherapy

2/2021	Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
8/2019	Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
1/2019	A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shunji Takahashi Research Topics

Disease

105	Neoplasms (Cancer) 04/2024 - 12/2002
69	Breast Neoplasms (Breast Cancer) 10/2023 - 01/2003
30	Sarcoma (Soft Tissue Sarcoma) 04/2024 - 01/2015
30	Neoplasm Metastasis (Metastasis) 09/2023 - 12/2002
21	Thyroid Neoplasms (Thyroid Cancer) 04/2024 - 12/2015
14	Head and Neck Neoplasms (Head and Neck Cancer) 04/2024 - 05/2011
14	Disease Progression 10/2023 - 04/2015
14	Prostatic Neoplasms (Prostate Cancer) 05/2023 - 05/2010
13	Squamous Cell Carcinoma of Head and Neck 03/2024 - 05/2013
13	Renal Cell Carcinoma (Grawitz Tumor) 05/2023 - 05/2008
11	Carcinoma (Carcinomatosis) 01/2024 - 12/2002
9	Neutropenia 01/2023 - 04/2014
9	Anaplastic Thyroid Carcinoma 01/2022 - 10/2013
7	Osteoporosis 05/2023 - 05/2010
7	Stomach Neoplasms (Stomach Cancer) 01/2023 - 01/2016
6	Bone Resorption 03/2013 - 01/2003
5	Anorexia 01/2023 - 11/2011
5	Colorectal Neoplasms (Colorectal Cancer) 05/2022 - 09/2012
5	Fatigue 03/2022 - 11/2011
5	Lymphoma (Lymphomas) 06/2021 - 01/2006
5	Diarrhea 01/2019 - 02/2002
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2023 - 01/2020
4	Adenoid Cystic Carcinoma (Cylindroma) 01/2023 - 08/2021
4	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2022 - 09/2005
4	Exanthema (Rash) 10/2022 - 01/2007
4	Febrile Neutropenia 01/2022 - 10/2015
4	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2021 - 05/2008
4	Infections 01/2021 - 10/2008
4	Nausea 10/2017 - 01/2007
3	Drug-Related Side Effects and Adverse Reactions 02/2024 - 01/2020
3	Esophageal Squamous Cell Carcinoma 10/2022 - 01/2017
3	Pain (Aches) 10/2022 - 01/2010
3	Neuroendocrine Carcinoma 05/2022 - 05/2005
3	medullary Thyroid cancer 01/2020 - 02/2017

Drug/Important Bio-Agent (IBA)

23	lenvatinibIBA 04/2024 - 12/2015
15	Cisplatin (Platino)FDA LinkGeneric 09/2023 - 05/2005
15	Docetaxel (Taxotere)FDA Link 08/2019 - 04/2003
13	TrabectedinIBA 01/2023 - 04/2015
12	Biomarkers (Surrogate Marker)IBA 03/2024 - 09/2003
12	Hormones (Hormone)IBA 10/2023 - 04/2009
12	eribulin FDA Link 01/2023 - 01/2016
11	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2004
10	ErbB Receptors (EGF Receptor)IBA 01/2024 - 11/2014
10	Trastuzumab (Herceptin)FDA Link 09/2023 - 01/2004
10	pazopanib FDA Link 01/2023 - 05/2015
10	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2007
10	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 01/2004
10	NivolumabIBA 01/2022 - 10/2017
9	Immune Checkpoint InhibitorsIBA 03/2024 - 04/2020
9	Phosphotransferases (Kinase)IBA 01/2023 - 01/2007
9	AnthracyclinesIBA 07/2016 - 01/2009
8	PlatinumIBA 01/2023 - 05/2013
8	Capecitabine (Xeloda)FDA Link 01/2016 - 03/2007
7	trastuzumab deruxtecanIBA 01/2024 - 01/2019
7	Diphosphonates (Bisphosphonates)IBA 05/2023 - 01/2003
7	Aromatase InhibitorsIBA 05/2023 - 03/2011
7	Denosumab FDA Link 05/2023 - 01/2012
7	taxaneIBA 07/2016 - 02/2010
6	IodineIBA 04/2024 - 01/2017
6	Fluorouracil (Carac)FDA LinkGeneric 09/2023 - 01/2006
6	AndrogensIBA 05/2023 - 05/2010
6	pembrolizumabIBA 01/2023 - 01/2020
6	Cetuximab (Erbitux)FDA Link 12/2022 - 05/2013
6	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 04/2011
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2021 - 01/2006
6	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 05/2008
6	Sunitinib (Sutent)FDA Link 03/2018 - 04/2011
6	Rituximab (Mabthera)FDA Link 08/2010 - 01/2006
5	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 02/2024 - 10/2016
5	Monoclonal AntibodiesIBA 04/2020 - 06/2015
5	Phenobarbital (Luminal)FDA Link 01/2018 - 03/2014
4	Circulating Tumor DNAIBA 03/2024 - 01/2019
4	DNA (Deoxyribonucleic Acid)IBA 04/2023 - 04/2009
4	RNA (Ribonucleic Acid)IBA 04/2023 - 01/2008
4	Tumor Biomarkers (Tumor Markers)IBA 05/2022 - 04/2006
4	CytokinesIBA 01/2021 - 01/2012
4	C-Reactive ProteinIBA 01/2021 - 01/2013
4	Zoledronic Acid (Zometa)FDA Link 10/2013 - 01/2012
4	Collagen Type I (Type I Collagen)IBA 03/2013 - 09/2003
3	Immunoconjugates (Immunoconjugate)IBA 10/2023 - 01/2020
3	Carboplatin (JM8)FDA LinkGeneric 01/2023 - 09/2016
3	LigandsIBA 10/2022 - 03/2018
3	Estrogen ReceptorsIBA 05/2022 - 03/2014
3	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2021 - 10/2013
3	Vincristine (Oncovin)FDA LinkGeneric 06/2021 - 05/2008
3	Prednisolone (Predate)FDA LinkGeneric 01/2021 - 01/2019
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 09/2019
3	AntibodiesIBA 01/2021 - 01/2006

Therapy/Procedure

79	Therapeutics 04/2024 - 02/2002
73	Drug Therapy (Chemotherapy) 09/2023 - 04/2003
9	Combination Drug Therapy (Combination Chemotherapy) 09/2016 - 01/2004
8	Castration 04/2021 - 02/2011
7	Neoadjuvant Therapy 01/2021 - 02/2010
6	Radiotherapy 09/2023 - 09/2005
5	Drug Tapering 01/2022 - 02/2002
4	Time-to-Treatment 01/2020 - 04/2009
3	Chemoradiotherapy 01/2023 - 02/2016
3	Induction Chemotherapy 02/2021 - 01/2019
3	Immunotherapy 09/2020 - 01/2013
3	Salvage Therapy 04/2020 - 02/2002